Boston Trust Walden Corp Has $38.13 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Boston Trust Walden Corp decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 9.9% during the first quarter, HoldingsChannel reports. The firm owned 643,340 shares of the company’s stock after selling 70,432 shares during the quarter. Boston Trust Walden Corp’s holdings in Prestige Consumer Healthcare were worth $38,131,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Lido Advisors LLC grew its holdings in Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after acquiring an additional 192 shares during the last quarter. Cerity Partners LLC raised its stake in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. lifted its holdings in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its stake in Prestige Consumer Healthcare by 4.6% during the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock worth $354,000 after purchasing an additional 256 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $70.75.

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Stock Down 0.1%

Shares of NYSE:PBH opened at $49.38 on Friday. The firm has a market capitalization of $2.34 billion, a PE ratio of 12.63, a price-to-earnings-growth ratio of 1.59 and a beta of 0.35. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $80.69. The firm has a fifty day moving average of $49.36 and a 200 day moving average of $58.27.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. During the same period in the prior year, the business posted $1.32 earnings per share. The business’s quarterly revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).